Prescient signs CAR-T agreement with Peter Mac Cancer Centre
Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with...
Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this morning, after strengthening its...
Prescient Therapeutics has inked a new deal with leading research organisation Peter MacCallum Cancer Centre...
With the number of days left to file March quarterly reports running a little short...
Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat...
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion...
When JVC launched VHS videos in 1971, it started a consumer revolution that permanently altered...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.